Publication | Closed Access

Enhanced antitumor and anti-metastasis efficacy against aggressive breast cancer with a fibronectin-targeting liposomal doxorubicin

Enhanced AntitumorBreast OncologyMedicineAggressive Breast CancerPathologyFibronectin-targeting Liposomal DoxorubicinBreast CancerTumor TargetingAnti-cancer AgentCancer TreatmentOncologyRadiation OncologyTumor Microenvironment